Antigen discovery and delivery of subunit vaccines by nonliving bacterial ghost vectors.
The bacterial ghost (BG) platform system is a novel vaccine delivery system endowed with intrinsic adjuvant properties. BGs are nonliving Gram-negative bacterial cell envelopes which are devoid of their cytoplasmic contents, yet maintain their cellular morphology and antigenic structures, including bioadhesive properties. The main advantages of BGs as carriers of subunit vaccines include their ability to stimulate a high immune response and to target the carrier itself to primary antigen-presenting cells. The intrinsic adjuvant properties of BGs enhance the immune response to target antigens, including T-cell activation and mucosal immunity. Since native and foreign antigens can be carried in the envelope complex of BGs, combination vaccines with multiple antigens of diverse origin can be presented to the immune system simultaneously. Beside the capacity of BGs to function as carriers of protein antigens, they also have a high loading capacity for DNA. Thus, loading BGs with recombinant DNA takes advantage of the excellent bioavailability for DNA-based vaccines and the high expression rates of the DNA-encoded antigens in target cell types such as macrophages and dendritic cells. There are many spaces within BGs including the inner and outer membranes, the periplasmic space and the internal lumen which can carry antigens, DNA or mediators of the immune response. All can be used for subunit antigen to design new vaccine candidates with particle presentation technology. In addition, the fact that BGs can also carry piggyback large-size foreign antigen particles, increases the technologic usefulness of BGs as combination vaccines against viral and bacterial pathogens. Furthermore, the BG antigen carriers can be stored as freeze-dried preparations at room temperature for extended periods without loss of efficacy. The potency, safety and relatively low production cost of BGs offer a significant technical advantage over currently utilized vaccine technologies.
Walcher
Petra
P
Institute of Microbiology and Genetics, Department Microbiology and Biotechnology, University of Vienna, UZA II, 2B255, Althanstrasse 14, A-1090 Wien, Austria.
Mayr
Ulrike B
UB
Azimpour-Tabrizi
Chakameh
C
Eko
Francis O
FO
Jechlinger
Wolfgang
W
Mayrhofer
Peter
P
Alefantis
Tim
T
Mujer
Cesar V
CV
DelVecchio
Vito G
VG
Lubitz
Werner
W
D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial / Q000276:immunology*; D010584:Bacteriophage phi X 174 / Q000235:genetics / Q000254:growth & development; D016503:Drug Delivery Systems; D005822:Genetic Vectors; D006090:Gram-Negative Bacteria / Q000276:immunology*; D019444:Vaccines, DNA / Q000008:administration & dosage; D022223:Vaccines, Subunit / Q000008:administration & dosage*
D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial; D019444:Vaccines, DNA; D022223:Vaccines, Subunit